Literature DB >> 2424526

A comparison of tumor-related antigens in male and female breast cancer.

J Lundy, Y Mishriki, M V Viola, S Chao, B Kasa, S Oravez, A Schuss.   

Abstract

A retrospective analysis was undertaken in which 15 female and 15 male breast cancers were matched by age, stage, estrogen receptor status, and histologic type. Our protocol compares male and female breast cancers for reactivity with antibodies against tumor-associated antigens known to be present on female breast cancer cells. Formalin-fixed sections of each primary tumor were reacted in the ABC immunoperoxidase assay against antibodies B72.3 and DF.3 and an antibody to the ras p21 antigen. Reactivity to B72.3 and DF.3 was similar. However, the ras p21 antigen was expressed to a significantly greater extent in female breast cancers (p = .0008). Thus, although there are similarities in antigenic phenotype of male and female breast cancers, some female breast cancers may have a different pathogenesis as demonstrated by increased amounts of a specific oncogene product.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424526     DOI: 10.1007/bf01806793

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

Review 1.  Carcinoma of the male breast: a thirty year experience and literature review.

Authors:  B Roswit; H Edlis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1978 Jul-Aug       Impact factor: 7.038

2.  Male breast cancer: a clinicopathologic study of 97 cases.

Authors:  K S Heller; P P Rosen; D Schottenfeld; R Ashikari; D W Kinne
Journal:  Ann Surg       Date:  1978-07       Impact factor: 12.969

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  The role of orchiectomy in the management of advanced male breast cancer.

Authors:  J P Neifeld; F Meyskens; D C Tormey; N Javadpour
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

5.  Carcinoma of the male breast: report of a series of 88 cases.

Authors:  A O Langlands; N Maclean; G R Kerr
Journal:  Clin Radiol       Date:  1976-01       Impact factor: 2.350

6.  Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.

Authors:  P H Hand; A Thor; D Wunderlich; R Muraro; A Caruso; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

7.  Prognostic factors in patients with stage I, estrogen receptor-negative carcinoma of the breast. A clinicopathologic study.

Authors:  T W Bauer; D O'Ceallaigh; J C Eggleston; G W Moore; R R Baker
Journal:  Cancer       Date:  1983-10-15       Impact factor: 6.860

8.  Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases.

Authors:  A Thor; P Horan Hand; D Wunderlich; A Caruso; R Muraro; J Schlom
Journal:  Nature       Date:  1984 Oct 11-17       Impact factor: 49.962

9.  Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.

Authors:  J Lundy; A Thor; R Maenza; J Schlom; F Forouhar; M Testa; D Kufe
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

10.  ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma.

Authors:  M V Viola; F Fromowitz; S Oravez; S Deb; J Schlom
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.